Cover Image
市場調查報告書

前列腺癌治療藥市場分析·預測

Prostate Cancer Disease Coverage Forecast and Market Analysis to 2024

出版商 Datamonitor Healthcare 商品編碼 604013
出版日期 內容資訊 英文 699 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
前列腺癌治療藥市場分析·預測 Prostate Cancer Disease Coverage Forecast and Market Analysis to 2024
出版日期: 2018年01月18日 內容資訊: 英文 699 Pages
簡介

本報告提供前列腺癌治療藥市場相關調查分析,提供市場預測,治療,流行病學,上市藥,開發平台藥物趨勢等系統性資訊。

預測:前列腺癌治療藥 (2018年1月18日出版)

  • 摘要整理
  • 市場動態
  • 預測·未來趨勢
  • 市場定義·調查手法
  • 一次調查手法
  • 參考資料
  • 產品簡介 (後期階段):DCVAC/PCA
  • 產品簡介: ELIGARD
  • 產品簡介: FIRMAGON
  • 產品簡介: JEVTANA
  • 產品簡介: LUPRON
  • 產品簡介 (後期階段): LYNPARZA
  • 產品簡介: PROVENGE
  • 產品簡介 (後期階段): RUBRACA
  • 產品簡介 (後期階段): TECENTRIQ
  • 產品簡介: TRELSTAR
  • 產品簡介: XOFIGO
  • 產品簡介: XTANDI
  • 產品簡介 (後期階段): YONSA
  • 產品簡介: ZOLADEX
  • 產品簡介: ZYTIGA
  • 產品簡介 (後期階段): APALUTAMIDE
  • 產品簡介 (後期階段): DAROLUTAMIDE
  • 產品簡介 (後期階段): IPATASERTIB
  • 產品簡介 (後期階段): MASITINIB
  • 產品簡介 (後期階段): RELUGOLIX

治療:前列腺癌治療藥 (2017年11月20日出版)

  • 摘要整理
  • 一次調查手法
  • 疾病定義·診斷
  • 患者區分
  • 目前治療選擇
  • 處方趨勢

流行病學:美國·前列腺癌治療藥 (2017年9月8日出版)

  • 摘要整理
  • 疾病的背景
  • 調查手法
  • 預測
  • 參考資料
  • 附錄

上市藥:前列腺癌治療藥 (2018年1月18日出版)

  • 摘要整理
  • 產品概要
  • 產品簡介: ELIGARD
  • 產品簡介: FIRMAGON
  • 產品簡介: JEVTANA
  • 產品簡介: LUPRON
  • 產品簡介: PROVENGE
  • 產品簡介: TRELSTAR
  • 產品簡介: XOFIGO
  • 產品簡介: XTANDI
  • 產品簡介: ZOLADEX
  • 產品簡介: ZYTIGA
  • 前列腺癌治療藥的價格·醫療費給付·取用(2016年7月5日出版)
  • 摘要整理
  • 市場背景
  • 全球的企業·主要意見領袖的考察
  • 美國的價格
  • 美國的企業·主要意見領袖的考察
  • 美國家的醫療費用給付
  • 日本
  • EU 市場上價格主要5個國家
  • EU 主要5個國家的企業·主要意見領袖的考察
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國

開發平台:前列腺癌治療藥 (2018年1月18日出版)

  • 摘要整理
  • 臨床開發平台概要
  • 臨床實驗設計
  • 最近中止的藥物
  • 產品簡介 (後期階段): DCVAC/PCA
  • 產品簡介 (後期階段): LYNPARZA
  • 產品簡介 (後期階段): RUBRACA
  • 產品簡介 (後期階段): TECENTRIQ
  • 產品簡介 (後期階段): YONSA
  • 產品簡介 (後期階段): APALUTAMIDE
  • 產品簡介 (後期階段): DAROLUTAMIDE
  • 產品簡介 (後期階段): IPATASERTIB
  • 產品簡介 (後期階段): MASITINIB
  • 產品簡介 (後期階段): RELUGOLIX
目錄
Product Code: DMKC 5797

DISEASE OVERVIEW

Prostate cancer is a hormonally fueled disease, and the most common form of cancer found in males. Consequently, there is a high incentive for drug development in this indication due to its large population size. While hormone-sensitive prostate cancer is well managed in terms of treatment options, unmet need persists for patients with prostate cancer that is no longer responsive to hormonal manipulation. Newly approved therapies for castration-resistant prostate cancer are set to create a shift in the way that the disease is treated, while creating a competitive environment for new market entrants.

Market snapshot

Zytiga will face generic erosion, ensuring Xtandi remains the most valuable brand over the forecast period.

ADT remains the most popular treatment choice for the majority of prostate cancer patients.

Label expansions into earlier treatment settings will help Xtandi combat growing competition.

Treatment may become more segmented as pipeline drugs with new mechanisms of action reach the market.

Drugs targeting non-metastatic CRPC will need to engage in rebate contracting in the US and in outcome-based risk-sharing agreements in the EU.

Table of Contents

  • FORECAST: PROSTATE CANCER (Published on 18 January 2018)
  • EXECUTIVE SUMMARY
  • MARKET DYNAMICS
  • FORECAST AND FUTURE TRENDS
  • MARKET DEFINITION AND METHODOLOGY
  • PRIMARY RESEARCH METHODOLOGY
  • BIBLIOGRAPHY
  • PRODUCT PROFILE (LATE STAGE): DCVAC/PCA
  • PRODUCT PROFILE: ELIGARD
  • PRODUCT PROFILE: FIRMAGON
  • PRODUCT PROFILE: JEVTANA
  • PRODUCT PROFILE: LUPRON
  • PRODUCT PROFILE (LATE STAGE): LYNPARZA
  • PRODUCT PROFILE: PROVENGE
  • PRODUCT PROFILE (LATE STAGE): RUBRACA
  • PRODUCT PROFILE (LATE STAGE): TECENTRIQ
  • PRODUCT PROFILE: TRELSTAR
  • PRODUCT PROFILE: XOFIGO
  • PRODUCT PROFILE: XTANDI
  • PRODUCT PROFILE (LATE STAGE): YONSA
  • PRODUCT PROFILE: ZOLADEX
  • PRODUCT PROFILE: ZYTIGA
  • PRODUCT PROFILE (LATE STAGE): APALUTAMIDE
  • PRODUCT PROFILE (LATE STAGE): DAROLUTAMIDE
  • PRODUCT PROFILE (LATE STAGE): IPATASERTIB
  • PRODUCT PROFILE (LATE STAGE): MASITINIB
  • PRODUCT PROFILE (LATE STAGE): RELUGOLIX
  • TREATMENT: PROSTATE CANCER (Published on 20 November 2017)
  • EXECUTIVE SUMMARY
  • PRIMARY RESEARCH METHODOLOGY
  • DISEASE DEFINITION AND DIAGNOSIS
  • PATIENT SEGMENTATION
  • CURRENT TREATMENT OPTIONS
  • PRESCRIBING TRENDS
  • EPIDEMIOLOGY: PROSTATE CANCER (Published on 08 September 2017)
  • EXECUTIVE SUMMARY
  • DISEASE BACKGROUND
  • METHODOLOGY
  • FORECAST
  • BIBLIOGRAPHY
  • APPENDIX: ADDITIONAL SOURCES
  • MARKETED DRUGS: PROSTATE CANCER (Published on 18 January 2018)
  • EXECUTIVE SUMMARY
  • PRODUCT OVERVIEW
  • PRODUCT PROFILE: ELIGARD
  • PRODUCT PROFILE: FIRMAGON
  • PRODUCT PROFILE: JEVTANA
  • PRODUCT PROFILE: LUPRON
  • PRODUCT PROFILE: PROVENGE
  • PRODUCT PROFILE: TRELSTAR
  • PRODUCT PROFILE: XOFIGO
  • PRODUCT PROFILE: XTANDI
  • PRODUCT PROFILE: ZOLADEX
  • PRODUCT PROFILE: ZYTIGA
  • PROSTATE CANCER PRICING, REIMBURSEMENT, AND ACCESS (Published on 05 July 2016)
  • EXECUTIVE SUMMARY
  • MARKET CONTEXT
  • GLOBAL PAYER AND KEY OPINION LEADER INSIGHTS
  • US PRICING
  • US PAYER AND KEY OPINION LEADER INSIGHTS
  • US REIMBURSEMENT
  • JAPAN
  • PRICING IN THE FIVE MAJOR EU MARKETS
  • FIVE MAJOR EU MARKETS PAYER AND KEY OPINION LEADER INSIGHTS
  • FRANCE
  • GERMANY
  • ITALY
  • SPAIN
  • UK
  • APPENDIX
  • PIPELINE: PROSTATE CANCER (Published on 18 January 2018)
  • EXECUTIVE SUMMARY
  • CLINICAL PIPELINE OVERVIEW
  • CLINICAL TRIAL DESIGN
  • RECENTLY DISCONTINUED DRUGS
  • PRODUCT PROFILE (LATE STAGE): DCVAC/PCA
  • PRODUCT PROFILE (LATE STAGE): LYNPARZA
  • PRODUCT PROFILE (LATE STAGE): RUBRACA
  • PRODUCT PROFILE (LATE STAGE): TECENTRIQ
  • PRODUCT PROFILE (LATE STAGE): YONSA
  • PRODUCT PROFILE (LATE STAGE): APALUTAMIDE
  • PRODUCT PROFILE (LATE STAGE): DAROLUTAMIDE
  • PRODUCT PROFILE (LATE STAGE): IPATASERTIB
  • PRODUCT PROFILE (LATE STAGE): MASITINIB
  • PRODUCT PROFILE (LATE STAGE): RELUGOLIX

LIST OF FIGURES

  • Figure 1: Prostate cancer - current and future market dynamics analysis
  • Figure 2: Datamonitor Healthcare's assessment summary of key marketed and pipeline drugs for prostate cancer
  • Figure 3: Prostate cancer sales across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 4: Prostate cancer sales across the US, Japan, and five major EU markets, by class, 2017-26
  • Figure 5: Generics sales in prostate cancer across the US, Japan, and five major EU markets, by drug, 2017-26
  • Figure 6: Xtandi sales in prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 7: Pipeline next-generation hormone therapy sales in prostate cancer across the US, Japan, and five major EU markets, by drug, 2017-26
  • Figure 8: Autologous vaccine sales in prostate cancer across the US, Japan, and five major EU markets, by drug, 2017-26
  • Figure 9: Targeted pipeline therapy sales in prostate cancer across the US, Japan, and five major EU markets, by drug, 2017-26
  • Figure 10: Patient-based forecast methodology for prostate cancer
  • Figure 11: Price sources and calculations, by country
  • Figure 12: DCVAC/PCa for prostate cancer - SWOT analysis
  • Figure 13: Datamonitor Healthcare's drug assessment summary of DCVAC/PCa for prostate cancer
  • Figure 14: Datamonitor Healthcare's drug assessment summary of DCVAC/PCa for prostate cancer
  • Figure 15: DCVAC/PCa sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 16: Eligard sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 17: Firmagon sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 18: Jevtana for prostate cancer - SWOT analysis
  • Figure 19: Datamonitor Healthcare's drug assessment summary of Jevtana for prostate cancer
  • Figure 20: Datamonitor Healthcare's drug assessment summary of Jevtana for prostate cancer
  • Figure 21: Jevtana sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 22: Lupron sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 23: Lynparza for prostate cancer - SWOT analysis
  • Figure 24: Datamonitor Healthcare's drug assessment summary of Lynparza for prostate cancer
  • Figure 25: Datamonitor Healthcare's drug assessment summary of Lynparza for prostate cancer
  • Figure 26: Lynparza sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 27: Provenge for prostate cancer - SWOT analysis
  • Figure 28: Datamonitor Healthcare's drug assessment summary of Provenge for prostate cancer
  • Figure 29: Datamonitor Healthcare's drug assessment summary of Provenge for prostate cancer
  • Figure 30: Provenge sales for prostate cancer in the US, 2017-26
  • Figure 31: Rubraca for prostate cancer - SWOT analysis
  • Figure 32: Datamonitor Healthcare's drug assessment summary of Rubraca for prostate cancer
  • Figure 33: Datamonitor Healthcare's drug assessment summary of Rubraca for prostate cancer
  • Figure 34: Rubraca sales for prostate cancer across the US and five major EU markets, by country, 2017-26
  • Figure 35: Tecentriq for prostate cancer - SWOT analysis
  • Figure 36: Datamonitor Healthcare's drug assessment summary of Tecentriq for prostate cancer
  • Figure 37: Datamonitor Healthcare's drug assessment summary of Tecentriq for prostate cancer
  • Figure 38: Tecentriq sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 39: Trelstar sales for prostate cancer across the US and five major EU markets, by country, 2017-26
  • Figure 40: Xofigo for prostate cancer - SWOT analysis
  • Figure 41: Datamonitor Healthcare's drug assessment summary of Xofigo for prostate cancer
  • Figure 42: Datamonitor Healthcare's drug assessment summary of Xofigo for prostate cancer
  • Figure 43: Xofigo sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 44: Xtandi for prostate cancer - SWOT analysis
  • Figure 45: Datamonitor Healthcare's drug assessment summary of Xtandi for prostate cancer
  • Figure 46: Datamonitor Healthcare's drug assessment summary of Xtandi for prostate cancer
  • Figure 47: Xtandi sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 48: Yonsa for prostate cancer - SWOT analysis
  • Figure 49: Datamonitor Healthcare's drug assessment summary of Yonsa for prostate cancer
  • Figure 50: Datamonitor Healthcare's drug assessment summary of Yonsa for prostate cancer
  • Figure 51: Yonsa sales for prostate cancer in the US, 2017-26
  • Figure 52: Zoladex sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 53: Zytiga for prostate cancer - SWOT analysis
  • Figure 54: Datamonitor Healthcare's drug assessment summary of Zytiga for prostate cancer
  • Figure 55: Datamonitor Healthcare's drug assessment summary of Zytiga for prostate cancer
  • Figure 56: Zytiga sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 57: Apalutamide for prostate cancer - SWOT analysis
  • Figure 58: Datamonitor Healthcare's drug assessment summary of apalutamide for prostate cancer
  • Figure 59: Datamonitor Healthcare's drug assessment summary of apalutamide for prostate cancer
  • Figure 60: Apalutamide sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 61: Darolutamide for prostate cancer - SWOT analysis
  • Figure 62: Datamonitor Healthcare's drug assessment summary of darolutamide for prostate cancer
  • Figure 63: Datamonitor Healthcare's drug assessment summary of darolutamide for prostate cancer
  • Figure 64: Darolutamide sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 65: Ipatasertib for prostate cancer - SWOT analysis
  • Figure 66: Datamonitor Healthcare's drug assessment summary of ipatasertib for prostate cancer
  • Figure 67: Datamonitor Healthcare's drug assessment summary of ipatasertib for prostate cancer
  • Figure 68: Ipatasertib sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 69: Masitinib for prostate cancer - SWOT analysis
  • Figure 70: Datamonitor Healthcare's drug assessment summary of masitinib for prostate cancer
  • Figure 71: Datamonitor Healthcare's drug assessment summary of masitinib for prostate cancer
  • Figure 72: Masitinib sales for prostate cancer across the five major EU markets, by country, 2017-26
  • Figure 73: Relugolix for prostate cancer - SWOT analysis
  • Figure 74: Datamonitor Healthcare's drug assessment summary of relugolix for prostate cancer
  • Figure 75: Datamonitor Healthcare's drug assessment summary of relugolix for prostate cancer
  • Figure 76: Relugolix sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 77: Localized prostate cancer patients receiving each type of treatment, by country
  • Figure 78: Localized prostate cancer patients treated with pharmacological therapy + prostatectomy receiving neoadjuvant and/or adjuvant therapy
  • Figure 79: Localized prostate cancer patients treated with pharmacological therapy + radiotherapy receiving neoadjuvant, concurrent, and/or adjuvant therapy
  • Figure 80: Pharmacologically treated localized prostate cancer patients receiving each therapy type, by country
  • Figure 81: Top three regimens used in localized prostate cancer patients treated with ADT, by country
  • Figure 82: Locally advanced prostate cancer patients receiving each type of treatment, by country
  • Figure 83: Pharmacologically treated locally advanced prostate cancer patients receiving each therapy type, by country
  • Figure 84: Top three regimens used in locally advanced prostate cancer patients treated with ADT, by country
  • Figure 85: Metastatic castration-naive prostate cancer patients receiving each type of treatment, by country
  • Figure 86: Pharmacologically treated metastatic castration-naive prostate cancer patients receiving each therapy type, by country
  • Figure 87: Top three regimens used in metastatic castration-naive prostate cancer patients treated with ADT, by country
  • Figure 88: Recurrent/progressive prostate cancer patients receiving each type of treatment at first line, by country
  • Figure 89: Recurrent/progressive prostate cancer patients receiving each type of treatment at second line, by country
  • Figure 90: Pharmacologically treated recurrent/progressive prostate cancer patients receiving each therapy type at first and second line
  • Figure 91: Top three first-line regimens for recurrent/progressive prostate cancer patients treated with ADT, by country
  • Figure 92: Top three second-line regimens for recurrent/progressive prostate cancer patients treated with ADT, by country
  • Figure 93: nmCRPC patients receiving each type of treatment at first line, by country
  • Figure 94: nmCRPC patients receiving each type of treatment at second line, by country
  • Figure 95: Pharmacologically treated nmCRPC patients receiving each therapy type at first line and second line
  • Figure 96: Top three first-line regimens for nmCRPC patients treated with ADT, by country
  • Figure 97: Top three second-line regimens for nmCRPC patients treated with ADT, by country
  • Figure 98: Top three first-line regimens for nmCRPC patients treated with chemotherapy, by country
  • Figure 99: Top three second-line regimens for nmCRPC patients treated with chemotherapy, by country
  • Figure 100: mCRPC patients receiving each type of treatment at first line, by country
  • Figure 101: mCRPC patients receiving each type of treatment at second line, by country
  • Figure 102: mCRPC patients receiving each type of treatment at third line, by country
  • Figure 103: Pharmacologically treated mCRPC patients receiving each therapy type at first line, second line, and third line
  • Figure 104: Top three first-line regimens for mCRPC patients treated with ADT, by country
  • Figure 105: Top three second-line regimens for mCRPC patients treated with ADT, by country
  • Figure 106: Top three third-line regimens for mCRPC patients treated with ADT, by country
  • Figure 107: Top three first-line regimens for mCRPC patients treated with chemotherapy, by country
  • Figure 108: Top three second-line regimens for mCRPC patients treated with chemotherapy, by country
  • Figure 109: Top three third-line regimens for mCRPC patients treated with chemotherapy, by country
  • Figure 110: Top three first-line regimens for mCRPC patients treated with therapies other than ADT or chemotherapy, by country
  • Figure 111: Top three second-line regimens for mCRPC patients treated with therapies other than ADT or chemotherapy, by country
  • Figure 112: Top three third-line regimens for mCRPC patients treated with therapies other than ADT or chemotherapy, by country
  • Figure 113: Trends in incident cases of diagnosed prostate cancer in the US, Japan, and five major EU markets, 2014-34
  • Figure 114: Eligard sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 115: Firmagon sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 116: Jevtana for prostate cancer - SWOT analysis
  • Figure 117: Datamonitor Healthcare's drug assessment summary of Jevtana for prostate cancer
  • Figure 118: Datamonitor Healthcare's drug assessment summary of Jevtana for prostate cancer
  • Figure 119: Jevtana sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 120: Lupron sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 121: Provenge for prostate cancer - SWOT analysis
  • Figure 122: Datamonitor Healthcare's drug assessment summary of Provenge for prostate cancer
  • Figure 123: Datamonitor Healthcare's drug assessment summary of Provenge for prostate cancer
  • Figure 124: Provenge sales for prostate cancer in the US, 2017-26
  • Figure 125: Trelstar sales for prostate cancer across the US and five major EU markets, by country, 2017-26
  • Figure 126: Xofigo for prostate cancer - SWOT analysis
  • Figure 127: Datamonitor Healthcare's drug assessment summary of Xofigo for prostate cancer
  • Figure 128: Datamonitor Healthcare's drug assessment summary of Xofigo for prostate cancer
  • Figure 129: Xofigo sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 130: Xtandi for prostate cancer - SWOT analysis
  • Figure 131: Datamonitor Healthcare's drug assessment summary of Xtandi for prostate cancer
  • Figure 132: Datamonitor Healthcare's drug assessment summary of Xtandi for prostate cancer
  • Figure 133: Xtandi sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 134: Zoladex sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 135: Zytiga for prostate cancer - SWOT analysis
  • Figure 136: Datamonitor Healthcare's drug assessment summary of Zytiga for prostate cancer
  • Figure 137: Datamonitor Healthcare's drug assessment summary of Zytiga for prostate cancer
  • Figure 138: Zytiga sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 139: Use of Xtandi and Zytiga among non-ADT pharmacological therapies in chemotherapy-naive mCRPC patients (% of patients), by country
  • Figure 140: DCVAC/PCa for prostate cancer - SWOT analysis
  • Figure 141: Datamonitor Healthcare's drug assessment summary of DCVAC/PCa for prostate cancer
  • Figure 142: Datamonitor Healthcare's drug assessment summary of DCVAC/PCa for prostate cancer
  • Figure 143: DCVAC/PCa sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 144: Lynparza for prostate cancer - SWOT analysis
  • Figure 145: Datamonitor Healthcare's drug assessment summary of Lynparza for prostate cancer
  • Figure 146: Datamonitor Healthcare's drug assessment summary of Lynparza for prostate cancer
  • Figure 147: Lynparza sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 148: Rubraca for prostate cancer - SWOT analysis
  • Figure 149: Datamonitor Healthcare's drug assessment summary of Rubraca for prostate cancer
  • Figure 150: Datamonitor Healthcare's drug assessment summary of Rubraca for prostate cancer
  • Figure 151: Rubraca sales for prostate cancer across the US and five major EU markets, by country, 2017-26
  • Figure 152: Tecentriq for prostate cancer - SWOT analysis
  • Figure 153: Datamonitor Healthcare's drug assessment summary of Tecentriq for prostate cancer
  • Figure 154: Datamonitor Healthcare's drug assessment summary of Tecentriq for prostate cancer
  • Figure 155: Tecentriq sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 156: Yonsa for prostate cancer - SWOT analysis
  • Figure 157: Datamonitor Healthcare's drug assessment summary of Yonsa for prostate cancer
  • Figure 158: Datamonitor Healthcare's drug assessment summary of Yonsa for prostate cancer
  • Figure 159: Yonsa sales for prostate cancer in the US, 2017-26
  • Figure 160: Apalutamide for prostate cancer - SWOT analysis
  • Figure 161: Datamonitor Healthcare's drug assessment summary of apalutamide for prostate cancer
  • Figure 162: Datamonitor Healthcare's drug assessment summary of apalutamide for prostate cancer
  • Figure 163: Apalutamide sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 164: Darolutamide for prostate cancer - SWOT analysis
  • Figure 165: Datamonitor Healthcare's drug assessment summary of darolutamide for prostate cancer
  • Figure 166: Datamonitor Healthcare's drug assessment summary of darolutamide for prostate cancer
  • Figure 167: Darolutamide sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 168: Ipatasertib for prostate cancer - SWOT analysis
  • Figure 169: Datamonitor Healthcare's drug assessment summary of ipatasertib for prostate cancer
  • Figure 170: Datamonitor Healthcare's drug assessment summary of ipatasertib for prostate cancer
  • Figure 171: Ipatasertib sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 172: Masitinib for prostate cancer - SWOT analysis
  • Figure 173: Datamonitor Healthcare's drug assessment summary of masitinib for prostate cancer
  • Figure 174: Datamonitor Healthcare's drug assessment summary of masitinib for prostate cancer
  • Figure 175: Masitinib sales for prostate cancer across the five major EU markets, by country, 2017-26
  • Figure 176: Relugolix for prostate cancer - SWOT analysis
  • Figure 177: Datamonitor Healthcare's drug assessment summary of relugolix for prostate cancer
  • Figure 178: Datamonitor Healthcare's drug assessment summary of relugolix for prostate cancer
  • Figure 179: Relugolix sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26

LIST OF TABLES

  • Table 1: Prostate cancer sales across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 2: Prostate cancer sales across the US, Japan, and five major EU markets, by class ($m), 2017-26
  • Table 3: Generics sales in prostate cancer across the US, Japan, and five major EU markets, by drug ($m), 2017-26
  • Table 4: Xtandi sales in prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 5: Pipeline next-generation hormone therapy sales in prostate cancer across the US, Japan, and five major EU markets, by drug ($m), 2017-26
  • Table 6: Autologous vaccine sales in prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 7: Targeted pipeline therapy sales in prostate cancer across the US, Japan, and five major EU markets, by drug ($m), 2017-26
  • Table 8: Summary of drug classes and molecules included in Datamonitor Healthcare's prostate cancer patient-based forecast
  • Table 9: Exchange rates used for calculating prices
  • Table 10: Oncologists and urologists surveyed for the prostate cancer primary research study, 2017
  • Table 11: DCVAC/PCa drug profile
  • Table 12: DCVAC/PCa Phase III trial in prostate cancer
  • Table 13: DCVAC/PCa Phase I/II data in prostate cancer
  • Table 14: DCVAC/PCa sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 15: Eligard sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 16: Firmagon sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 17: Jevtana drug profile
  • Table 18: Jevtana pivotal Phase III data in prostate cancer
  • Table 19: Jevtana Phase III data in prostate cancer
  • Table 20: Jevtana sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 21: Lupron sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 22: Lynparza drug profile
  • Table 23: Lynparza Phase III trial in prostate cancer
  • Table 24: Lynparza Phase II data in prostate cancer
  • Table 25: Lynparza sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 26: Provenge drug profile
  • Table 27: Provenge pivotal Phase III data in prostate cancer
  • Table 28: Provenge sales for prostate cancer in the US ($m), 2017-26
  • Table 29: Rubraca drug profile
  • Table 30: Rubraca trials in prostate cancer
  • Table 31: Rubraca sales for prostate cancer across the US and five major EU markets, by country ($m), 2017-26
  • Table 32: Tecentriq drug profile
  • Table 33: Tecentriq Phase III trials in prostate cancer
  • Table 34: Tecentriq sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 35: Trelstar sales for prostate cancer across the US and five major EU markets, by country ($m), 2017-26
  • Table 36: Xofigo drug profile
  • Table 37: Xofigo Phase III data in prostate cancer
  • Table 38: Xofigo Phase III trials in prostate cancer
  • Table 39: Xofigo sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 40: Xtandi drug profile
  • Table 41: Xtandi Phase III data in prostate cancer
  • Table 42: Xtandi Phase III trials in prostate cancer
  • Table 43: Xtandi sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 44: Yonsa drug profile
  • Table 45: Yonsa Phase II/III trial in prostate cancer
  • Table 46: Yonsa sales for prostate cancer in the US ($m), 2017-26
  • Table 47: Zoladex sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 48: Zytiga drug profile
  • Table 49: Zytiga Phase III data in prostate cancer
  • Table 50: Zytiga Phase III trials in prostate cancer
  • Table 51: Zytiga sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 52: Apalutamide drug profile
  • Table 53: Apalutamide Phase III data in prostate cancer
  • Table 54: Apalutamide Phase I/II data in prostate cancer
  • Table 55: Apalutamide sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 56: Darolutamide drug profile
  • Table 57: Darolutamide Phase III trials in prostate cancer
  • Table 58: Darolutamide Phase I/II data in prostate cancer
  • Table 59: Darolutamide sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 60: Ipatasertib drug profile
  • Table 61: Ipatasertib Phase III trial in prostate cancer
  • Table 62: Ipatasertib Phase II data in prostate cancer
  • Table 63: Ipatasertib sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 64: Masitinib drug profile
  • Table 65: Masitinib Phase III trial in prostate cancer
  • Table 66: Masitinib Phase II data in prostate cancer
  • Table 67: Masitinib sales for prostate cancer across the five major EU markets, by country ($m), 2017-26
  • Table 68: Relugolix drug profile
  • Table 69: Relugolix Phase III trials in prostate cancer
  • Table 70: Relugolix Phase II data in prostate cancer
  • Table 71: Relugolix sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 72: Oncologists and urologists surveyed for the prostate cancer primary research study, 2017
  • Table 73: Percentage of US males who will develop prostate cancer over 10-, 20-, and 30-year intervals according to their current age, 2010-12
  • Table 74: Prostate cancer five-year relative survival rates in the US, by stage at diagnosis
  • Table 75: NCCN prostate cancer patient segmentation, by risk group
  • Table 76: ESMO prostate cancer patient segmentation, by risk group
  • Table 77: Prostate cancer segmentation using TNM stage, risk group, PSA measurement, and Gleason score
  • Table 78: Prostate cancer segmentation by clinical state
  • Table 79: Leading treatments for prostate cancer
  • Table 80: Cancer registry databases used as a source of prostate cancer incidence data, by country
  • Table 81: Forecasting methodology for prostate cancer incidence, by country, age group, and gender
  • Table 82: Sources of survival data used to estimate prostate cancer prevalence, by country
  • Table 83: Incident cases of prostate cancer in the US, Japan, and five major EU markets, by country, 2016-36
  • Table 84: Profiled key marketed drugs for prostate cancer
  • Table 85: Eligard sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 86: Firmagon sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 87: Jevtana drug profile
  • Table 88: Jevtana pivotal Phase III data in prostate cancer
  • Table 89: Jevtana Phase III data in prostate cancer
  • Table 90: Jevtana sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 91: Lupron sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 92: Provenge drug profile
  • Table 93: Provenge pivotal Phase III data in prostate cancer
  • Table 94: Provenge sales for prostate cancer in the US ($m), 2017-26
  • Table 95: Trelstar sales for prostate cancer across the US and five major EU markets, by country ($m), 2017-26
  • Table 96: Xofigo drug profile
  • Table 97: Xofigo Phase III data in prostate cancer
  • Table 98: Xofigo Phase III trials in prostate cancer
  • Table 99: Xofigo sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 100: Xtandi drug profile
  • Table 101: Xtandi Phase III data in prostate cancer
  • Table 102: Xtandi Phase III trials in prostate cancer
  • Table 103: Xtandi sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 104: Zoladex sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 105: Zytiga drug profile
  • Table 106: Zytiga Phase III data in prostate cancer
  • Table 107: Zytiga Phase III trials in prostate cancer
  • Table 108: Zytiga sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 109: Marketed prostate cancer products and approved indications in the US, Japan, and five major EU markets
  • Table 110: Late-stage candidates in development for prostate cancer
  • Table 111: Levers impacting access to prostate cancer drugs in the US and five major EU markets
  • Table 112: Phase III pivotal studies in non-metastatic CRPC
  • Table 113: Phase III trials in metastatic hormone-sensitive prostate cancer
  • Table 114: Studies of docetaxel in metastatic hormone-sensitive prostate cancer
  • Table 115: US pricing of marketed prostate cancer drugs
  • Table 116: Prostate cancer clinical pathway used by Anthem's Cancer Care Quality Program
  • Table 117: Formulary placement of prostate cancer drugs in selected commercial formularies
  • Table 118: Formulary placement of prostate cancer drugs in top four Medicare Part D formularies
  • Table 119: Pivotal trial data for Xtandi and Zytiga in chemotherapy-naive mCRPC
  • Table 120: Prior authorization criteria for Jevtana, Provenge, Xofigo, Xtandi, and Zytiga in four major health plans
  • Table 121: Pricing premiums given to medicines that can demonstrate benefit over comparators
  • Table 122: Pricing of key marketed prostate cancer drugs in Japan
  • Table 123: Price calculation methodologies for prostate cancer drugs in Japan launched after 2008
  • Table 124: Pricing of key prostate cancer drugs in the five major EU markets
  • Table 125: Transparency Committee's ASMR ratings and pricing implications
  • Table 126: Transparency Committee's SMR ratings and pricing implications
  • Table 127: Transparency Committee's assessment of prostate cancer treatments
  • Table 128: G-BA assessment of key prostate cancer therapies
  • Table 129: Classification of a new drug submission according to NUB status
  • Table 130: Reimbursement conditions for prostate cancer drugs in Italy
  • Table 131: Prostate cancer drug assessments by the Emilia-Romagna region
  • Table 132: Prostate cancer drug assessments by the Veneto region
  • Table 133: Comparing the Emilio-Romagna region to the Veneto region
  • Table 134: Spanish national and regional health reimbursement decisions for prostate cancer drugs
  • Table 135: Spanish Oncology Genitourinary Group recommendations for mCRPC
  • Table 136: NICE assessments of key prostate cancer therapies
  • Table 137: SMC decisions on key prostate cancer therapies
  • Table 138: Price sources and calculations, by country
  • Table 139: Exchange rates used for calculating prices
  • Table 140: Profiled pipeline products in development for prostate cancer
  • Table 141: Typical Phase III clinical trial design in prostate cancer
  • Table 142: Late-stage compound that was recently discontinued for prostate cancer
  • Table 143: DCVAC/PCa drug profile
  • Table 144: DCVAC/PCa Phase III trial in prostate cancer
  • Table 145: DCVAC/PCa Phase I/II data in prostate cancer
  • Table 146: DCVAC/PCa sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 147: Lynparza drug profile
  • Table 148: Lynparza Phase III trial in prostate cancer
  • Table 149: Lynparza Phase II data in prostate cancer
  • Table 150: Lynparza sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
  • Table 151: Rubraca drug profile
  • Table 152: Rubraca trials in prostate cancer
  • Table 153: Rubraca sales for prostate cancer across the US and five major EU markets, by country ($m), 2017-26
  • Table 154: Tecentriq drug profile
  • Table 155: Tecentriq Phase III trials in prostate cancer
  • Table 156: Tecentriq sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Back to Top